Synergistic cytotoxicity of recombinant IGFBP-3 and cisplatin in HPV18-positive HeLa cells via NF-κB inflammatory modulation

Hourolein Arab , Mohammad Shokrzadeh , Tahoora Mousavi, Mohammad Reza Mofid

Abstract


Background and purpose: Insulin-like growth factor-binding protein-3 (IGFBP-3), a tumor suppressor and inhibitor of nuclear factor kappa B (NF-κB), has emerged as a promising candidate for therapeutic application across diverse pathological conditions. Given NF-κB’s role in cervical cancer development and cisplatin resistance, this study examines the effects of recombinant human IGFBP-3 (rhIGFBP-3), alone and in combination with cisplatin, on NF-κB levels, inflammatory modulation, and apoptotic response in HeLa cells, and investigates whether rhIGFBP-3 can reduce the cisplatin dose.

Experimental approach: The impact of rhIGFBP-3, alone and in combination with cisplatin, on HeLa cells’ viability was evaluated by assessing cell viability (MTT assay); apoptosis (cell cycle analysis, TUNEL, annexin V/PI staining, Bax/Bcl-2 ratio, caspase activity); and NF-κB p65 levels (western blot). Gene expression of inflammatory cytokines and enzymes (IL-6, IL-8, COX-2, iNOS) was analyzed by RT-PCR.

Findings/Results: Cisplatin and rhIGFBP-3 inhibited HeLa cell growth in a concentration-dependent manner (IC₅₀ = 6.06 μg/mL and 1.12 μg/mL, respectively). Their combination exhibited synergistic cytotoxicity (combination index < 1), allowing ~2.1-fold reductions in concentration to 2.53 μg/mL cisplatin and 0.46 μg/mL rhIGFBP-3 for 45% growth inhibition. Compared to monotherapy, the combination significantly enhanced apoptosis and DNA fragmentation, sub-G1 accumulation, caspase-8/9/3/7 activation, and BAX/BCL-2 ratio. It also considerably reduced NF-κB p65 and inflammatory markers in comparison with cisplatin alone.

Conclusion and implications: Our study demonstrated that rhIGFBP-3 enhanced cisplatin efficacy by promoting apoptosis and attenuating inflammation, highlighting its potential as both a cisplatin adjuvant and a monotherapy in HeLa cells.

 


Keywords


Keywords: Apoptosis, Cervical cancer; Cisplatin; IGFBP-3; Inflammation; NF-κB.

Full Text:

PDF

References


Jallah JK, Anjankar A, Nankong FA. Public health approach in the elimination and control of cervical cancer: a review. Cureus. 2023;15(9):1-9.DOI: 10.7759/cureus.44543.

Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res. 2022;13:200238,1-14.DOI: 10.1016/j.tvr.2022.200238.

Romani AM. Cisplatin in cancer treatment. Biochem Pharmacol. 2022;206:115323.DOI: 10.1016/j.bcp.2022.115323.

Bhattacharjee R, Dey T, Kumar L, Kar S, Sarkar R, Ghorai M, et al. Cellular landscaping of cisplatin resistance in cervical cancer. Biomed Pharmacother. 2022;153:113345.DOI: 10.1016/j.biopha.2022.113345.

Vitkauskaite A, Urboniene D, Celiesiute J, Jariene K, Skrodeniene E, Nadisauskiene RJ, et al. Circulating inflammatory markers in cervical cancer patients and healthy controls. J Immunotoxicol. 2020;17(1): 105-109.DOI: 10.1080/1547691X.2020.1755397.

Revathidevi S, Murugan AK, Nakaoka H, Inoue I, Munirajan AK. APOBEC: a molecular driver in cervical cancer pathogenesis. Cancer Lett. 2021;496:104-116.DOI: 10.1016/j.canlet.2020.10.004.

Fernandes JV, de Medeiros Fernandes TAA, de Azevedo JCV, Cobucci RNO, de Carvalho MGF, Andrade VS, et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis. Oncol Lett. 2015;9(3):1015-1026.DOI: 10.3892/ol.2015.2884.

Deng S, Yuan P, Sun J. The role of NF-κB in carcinogenesis of cervical cancer: opportunities and challenges. Mol Biol Rep. 2024;51(1):538.DOI: 10.1007/s11033-024-09447-z.

Godwin P, Baird AM, Heavey S, Barr M, O’Byrne K, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3: 120,1-10.

DOI: 10.3389/fonc.2013.00120.

Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathog Dis. 2019;77(5):ftz048,1-11.DOI: 10.1093/femspd/ftz048.

da Costa RMG, Bastos MM, Medeiros R, Oliveira PA. The NFκB signaling pathway in papillomavirus-induced lesions: friend or foe? Anticancer Res. 2016;36(5): 2073-2083.

PMID: 27127107.

Hernandez-Flores G, Ortiz-Lazareno P, Lerma-Diaz J, Dominguez-Rodriguez J, Jave-Suarez L, Bravo-Cuellar A. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-κB and decreased cell senescence. BMC Cancer. 2011;11(1):483,1-15.DOI: 10.1186/1471-2407-11-483.

Garcia-Becerra N, Aguilar-Lemarroy A, Jave-Suarez LF. On the regulation of NF-κB pathway by HPV oncoproteins: are pathway inhibitors a good alternative for the treatment of cervical cancer? Anticancer Agents Med Chem. 2023;23(5):492-497.DOI: 10.2174/1871520622666220509180606.

Ansari A, Gheysarzadeh A, Sharifi A, Mofid MR. Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer. Res Pharm Sci. 2024;19(1):42-52.DOI: 10.4103/1735-5362.394819.

Yan J, Yang X, Li L, Liu P, Wu H, Liu Z, et al. Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma. Oncol Lett. 2017;13(5):3395-3402.DOI: 10.3892/ol.2017.5934.

Mofid MR, Gheysarzadeh A, Bakhtiyari S. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor. Pancreatology. 2020;20(7): 1442-1450.DOI: 10.1016/j.pan.2020.07.406.

Sharma M, Satyam A, Abhishek A, Khan R, Rajappa M, Sharma A. Molecular and circulatory expression of insulin growth factors in Indian females with advanced cervical cancer. Asian Pac J Cancer Prev. 2012;13(12):6475-6479.DOI: 10.7314/apjcp.2012.13.12.6475.

Mehta HH, Gao Q, Galet C, Paharkova V, Wan J, Said J, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71(15):5154-5163.DOI: 10.1158/0008-5472.CAN-10-4513.

Wang YA, Sun Y, Palmer J, Solomides C, Huang LC, Shyr Y, et al. IGFBP-3 modulates lung tumorigenesis and cell growth through IGF1 signaling. Mol Cancer Res. 2017;15(7):896-904.DOI: 10.1158/1541-7786.MCR-16-0390.

Li C, Harada A, Oh Y. IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78. Cancer Lett. 2012;325(2):200-206.DOI: 10.1016/j.canlet.2012.07.004.

Han J, Jogie-Brahim S, Harada A, Oh Y. Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett. 2011;307(2):200-210.DOI: 10.1016/j.canlet.2011.04.004.

Mohanraj L, Kim HS, Li W, Cai Q, Kim KE, Shin HJ, et al. IGFBP-3 inhibits cytokine-induced insulin resistance and early manifestations of atherosclerosis. PLoS One. 2013;8(1):e55084,1-13.DOI: 10.1371/journal.pone.0055084

Lee HS, Woo SJ, Koh HW, Ka SO, Zhou L, Jang KY, et al. Regulation of apoptosis and inflammatory responses by insulin‐like growth factor binding protein 3 in fibroblast‐like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis Rheumatol. 2014;66(4):863-873.DOI: 10.1002/art.38303.

Lee YC, Jogie-Brahim S, Lee DY, Han J, Harada A, Murphy LJ, et al. Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem. 2011;286(20):17898-17909.DOI: 10.1074/jbc.M111.231035.

Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, et al. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J. 2016;30(12):4071-4082.DOI: 10.1096/fj.201600427R.

Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.DOI: 10.1016/0065-2571(84)90007-4.

Pasha A, Kumar K, Heena S, Arnold Emerson I, Pawar SC. Inhibition of NF-κB and COX-2 by andrographolide regulates the progression of cervical cancer by promoting PTEN expression and suppressing PI3K/AKT signaling pathway. Sci Rep. 2024;14(1):12020,1-22.DOI: 10.1038/s41598-024-57304-7.

Sarwar S, Yu JQ, Nadeem H, Huq F. Synergistic cytotoxic effect from combination of wedelolactone and cisplatin in HeLa cell line: a novel finding. Drug Des Devel Ther. 2020;14:3841-3852.DOI: 10.2147/DDDT.S261321.

Bhatia K, Das A. Combinatorial drug therapy in cancer: new insights. Life Sci. 2020;258:118134,1-27.DOI: 10.1016/j.lfs.2020.118134.

Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Dürr PJ, et al. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer. 2009;16(3):795-808.DOI: 10.1677/ERC-08-0175.

Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000;275(50):39174-39181.DOI: 10.1074/jbc.M908888199.

Luo LL, Zhao L, Xi M, He LR, Shen JX, Li QQ, et al. Association of insulin‐like growth factor‐binding protein‐3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma. Cancer Commun. 2015;34(11):514-521.DOI: 10.1186/s40880-015-0046-2.

Schedlich LJ, Yenson VM, Baxter RC. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Mol Cell Endocrinol. 2013;377(1-2):56-64.DOI: 10.1016/j.mce.2013.06.033.

Lin M, Marzec K, Martin J, Baxter R. The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene. 2014;33(1):85-96.DOI: 10.1038/onc.2012.538.

Wang SH, Chen YL, Hsiao JR, Tsai FY, Jiang SS, Lee AYL, et al. Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-κB/IL-6/ROS signaling. J Exp Clin Cancer Res. 2021;40(1):95,1-18.DOI: 10.1186/s13046-021-01898-7.

Liu J, Guo Y, Huang Y, Xue H, Bai S, Zhu J, et al. Effects of insulin-like growth factor binding protein 3 on apoptosis of cutaneous squamous cell carcinoma cells. Onco Targets Ther. 2018;11:6569-6577.DOI: 10.2147/OTT.S167187.

Ng EFY, Kaida A, Nojima H, Miura M. Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line. Sci Rep. 2022;12(1):11503,1-14.DOI: 10.1038/s41598-022-15737-y.

Thota B, Arimappamagan A, Kandavel T, Shastry AH, Pandey P, Chandramouli BA, et al. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma. J Neurosurg. 2014;121(2):374-383.DOI: 10.3171/2014.4.JNS131198.

Chen CH, Chen PY, Lin YY, Feng LY, Chen SH, Chen CY, et al. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. J Neurosurg. 2019;132(1):168-179.DOI: 10.3171/2018.8.JNS181217.

Williams AC, Smartt H, Macfarlane M, Paraskeva C, Collard T. Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-κB. Cell Death Differ. 2007;14(1):137-145.DOI: 10.1038/sj.cdd.4401919.

Kielczewski JL, Hu P, Shaw LC, Calzi SL, Mames RN, Gardiner TA, et al. Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. Am J Pathol. 2011;178(4):1517-1528.DOI: 10.1016/j.ajpath.2010.12.031.

Wen SY, Ali A, Huang IC, Liu JS, Chen PY, Viswanadha VP, et al. Doxorubicin-induced ROS-dependent HIF1α activation mediates blockage of IGF1R survival signaling by IGFBP3 promotes cardiac apoptosis. Aging (Albany). 2023;15(1):164-178.DOI: 10.18632/aging. 204466.

Wu C, Liu X, Wang Y, Tian H, Xie Y, Li Q, et al. Insulin-like growth factor binding protein-3 promotes the G1 cell cycle arrest in several cancer cell lines. Gene. 2013;512(1):127-133.DOI: 10.1016/j.gene.2012.09.080.

Peng L, Wang J, Malloy PJ, Feldman D. The role of insulin‐like growth factor binding protein‐3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer. 2008;122(3):558-566.DOI: 10.1002/ijc.23100.

O'Han MK, Baxter RC, Schedlich LJ. Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors. 2009;27(6):394-408.DOI: 10.3109/08977190903185032.

Luo L, Zhao L, Wang Y, Tian X, Xi M, Shen J, et al. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. Sci Rep. 2015;5:17336,1-12.DOI: 10.1038/srep17336.

Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem. 2010;285(39):30233-30246.DOI: 10.1074/jbc.M110.122226.

Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 2004;64(6):2229-2237.DOI: 10.1158/0008-5472.can-03-1675.

D’Addio F, Maestroni A, Assi E, Ben Nasr M, Amabile G, Usuelli V, et al. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nat Commun. 2022;13(1):684,1-14.DOI: 10.1038/s41467-022-28360-2.

Agostini-Dreyer A, Jetzt AE, Stires H, Cohick WS. Endogenous IGFBP-3 mediates intrinsic apoptosis through modulation of Nur77 phosphorylation and nuclear export. Endocrinology. 2015;156(11):4141-4151.DOI: 10.1210/en.2015-1215.

Puar YR, Shanmugam MK, Fan L, Arfuso F, Sethi G, Tergaonkar V. Evidence for the involvement of the master transcription factor NF-κB in cancer initiation and progression. Biomedicines. 2018;6(3): 82,1-21.DOI: 10.3390/biomedicines6030082.

Moawadh MS, Mir R, Tayeb FJ, Asim O, Ullah MF. Molecular evaluation of the impact of polymorphic variants in apoptotic (Bcl-2/Bax) and proinflammatory cytokine (TNF-α/IL-8) genes on the susceptibility and progression of myeloproliferative neoplasms:a case-control biomarker study. Curr Issues Mol Biol. 2023;45(5):3933-3952.DOI: 10.3390/cimb45050251.

Shah A, Patel C. A concise review of inflammatory biomarkers targeted cancer therapy. Folia Med (Plovdiv). 2022;64(4):572-580.DOI: 10.3897/folmed.64.e68365.

Hafezi S, Rahmani M. Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers (Basel). 2021;13(6):1292,1-15.DOI: 10.3390/cancers13061292.

Pogmore JP, Uehling D, Andrews DW. Pharmacological targeting of executioner proteins: controlling life and death. J Med Chem. 2021;64(9):5276-5290.DOI: 10.1021/acs.jmedchem.0c02200.

Wu X, Sun L, Xu F. NF-κB in cell deaths, therapeutic resistance and nanotherapy of tumors: recent advances. Pharmaceuticals (Basel). 2023;16(6):783,1-22.DOI: 10.3390/ph16060783.

Akbarpour Arsanjani A, Abuei H, Behzad-Behbahani A, Bagheri Z, Arabsolghar R, Farhadi A. Activating transcription factor 3 inhibits NF‑κB p65 signaling pathway and mediates apoptosis and cell cycle arrest in cervical cancer cells. Infect Agent Cancer. 2022;17(1):62,1-10.DOI: 10.1186/s13027-022-00475-7.

Kang L, Li X, Liu J, Li Y, Li S, Zhao C. Recombinant human insulin-like growth factor binding protein 3 attenuates lipopolysaccharide-induced acute lung injury in mice. Int J Clin Exp Pathol. 2020;13(7): 1924-1931.PMID: 32782724.

Zhang XL, Li HH, Cao YP, Peng F, Li JP. Insulin-like growth factor binding protein 3 inhibits inflammatory response and promotes apoptosis in fibroblast-like synoviocytes of osteoarthritis. Int J Clin Exp Pathol. 2017;10:3024-3032.

Bogdan ED, Stuard WL, Titone R, Robertson DM. IGFBP-3 mediates metabolic homeostasis during hyperosmolar stress in the corneal epithelium. Invest Ophthalmol Vis Sci. 2021;62(7):11,1-11.DOI: 10.1167/iovs.62.7.11.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.